Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

ATENCION - Philippines FDA Drug Approval Details

Approvals/Philippines FDA/ATENCION

Approved

STANDARD

ATENCION

Pharmascience Inc.🇵🇭 Food and Drug Administration - Philippines

Approval Date: Jul 14, 2025
Approval ID: 806a88e897137d62
Company: Pharmascience Inc.
Type: Standard

Approval Details

Approval Id: 806a88e897137d62
Drug Approval Philippines Name: ATENCION
Product Name: ATENCION
Registration Number: DR-XY47032
Brand Name: ATENCION
Generic Name: Atomoxetine (As Hydrochloride)
Dosage Form: Capsule
Dosage Strength: 10mg
Manufacturer: Pharmascience Inc.
Importer: United Laboratories Inc.
Distributor: United Laboratories Inc.
Company Detail Path: /organization/pharmascience-inc
Issuance Date: 28 August 2020
Expiry Date: 28 August 2025
Classification: Prescription Drug (Rx)

Active Ingredients

Approved

Quick Info

Agency

Philippines FDA

Country

🇵🇭

Approval Date

Jul 14, 2025

Approval ID

806a88e897137d62

Type

Standard

Back to Philippines FDA Approvals